BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• FDA

  OnPoint Surgical Receives 510(k) Clearance for the OnPoint Augmented Reality Spine System

  OnPoint Surgical, Inc. today announced that the US Food and Drug Administration (FDA) has given clearance for the use of its OnPoint Augmented Reality Spine System.

  September 11, 2023

   · 

  3 min read
• Business

  Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress

  Autobahn Therapeutics today announced progress with its lead clinical candidate, ABX-002, and early pipeline advancements. In addition, the company further strengthened its senior leadership team with the promotion of Gudarz Davar, M.D., to Executive Vice President, Head of Research and Development.

  September 11, 2023

   · 

  5 min read
• Business

  DermTech Appoints Mark Aguillard as Chief Commercial Officer

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023.

  September 11, 2023

   · 

  5 min read
• Genetown

  Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives

  Enveric Biosciences today announced the filing of a provisional patent application to support its use of artificial intelligence (AI) based computational methods for identifying tryptamine derived new chemical entities (NCEs) and modeling interaction with the 5-HT2A receptor (5-HT2AR).

  September 11, 2023

   · 

  5 min read
• Biotech Beach

  Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings

  Lassen Therapeutics today announced new clinical and preclinical data generated with LASN01 at the 2023 European Respiratory Society (ERS) International Congress and the 45th Annual Meeting of the European Thyroid Association (ETA).

  September 11, 2023

   · 

  3 min read
• Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

  Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM.

  September 11, 2023

   · 

  4 min read
• GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry PartnerTrial to Assess Multi Cancer Genetic Risk Assessment in General Practice

  Genetic Technologies Limited is pleased to announce that a Medical Research Future Fund Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations.

  September 11, 2023

   · 

  4 min read
• Biotech Bay

  Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

  Day One Biopharmaceuticals today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).

  September 11, 2023

   · 

  9 min read
• Genetown

  CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

  Centogene N.V. today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

  September 11, 2023

   · 

  4 min read
• Pharm Country

  Avertix to Present at Two Upcoming Investor Conferences in September 2023

  Avertix Medical, Inc. today announces that Company management will participate in two investor conferences in the month of September 2023.

  September 11, 2023

   · 

  2 min read